The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1577
ISSUE1577
July 29, 2019
Addendum: Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
Download PDF: US English
Med Lett Drugs Ther. 2019 Jul 29;61(1577):120
Disclosures
Objective(s)
In our article on Bijuva, the oral fixed-dose combination of estradiol and progesterone (Med Lett Drugs Ther 2019; 61:99), Table 1 should have included single-ingredient oral formulations of estradiol and progesterone (see below). They will be added to the table as it appears online, along with medroxyprogesterone (Provera, and generics), another single-ingredient progestin available for use in women with an intact uterus who take systemic estrogen for menopausal symptoms. Taking generic estradiol and progesterone separately may be less convenient than taking Bijuva, but they cost less and allow for more dosing flexibility.
© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and
complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any
damage resulting from any error, inaccuracy, or omission.